Evaluation on safety of puerarin injection in clinical use.
10.19540/j.cnki.cjcmm.20180709.008
- Author:
Xiao-Shuai XIE
1
;
Yun-Zhuo DONG
1
;
Dian-Ping MU
1
;
Xiao-Lin PAN
1
;
Feng-Ying ZHANG
1
Author Information
1. Tianjin First Center Hospital, Tianjin 300192, China.
- Publication Type:Journal Article
- Keywords:
ADRs;
puerarin injection;
safety
- MeSH:
Aged;
Drugs, Chinese Herbal;
adverse effects;
therapeutic use;
Humans;
Injections;
Isoflavones;
adverse effects;
therapeutic use;
Middle Aged
- From:
China Journal of Chinese Materia Medica
2018;43(19):3956-3961
- CountryChina
- Language:Chinese
-
Abstract:
Puerarin injection is commonly used in clinical treatment of coronary heart disease, angina pectoris, retinal artery, vein occlusion, sudden deafness and so on. This paper is aimed to evaluate the safety of puerarin injection in clinical use and explore the related factors that may cause its adverse reactions (ADRs), so as to find the warning signal of safety medication in time, put forward early warning, make early judgment and treatment, and ensure the safety of drug use. By strengthening surveillance, the best medication plan was established to prevent the occurrence of adverse reactions of puerarin injection and enhance people's awareness on the safety of puerarin injection. Database were searched to collect literature related to ADRs of puerarin injection. The data were extracted and analyzed by decision tree with treeage software and ² test was used to verify the data. A total of 62 papers involving 129 cases were included. The results showed that ADRs occurred mostly in patients aged 50-79 years, with the immune system and blood system accounting for the majority (88.3%), and ADRs occurred mostly 48 h after drug administration (61.1%). The severity of ADRs was not related to the dosage of puerarin, but it was related to the choice of the infusion solvent. In puerarin injection, most of the ADRs were moderate or severe (64.3%), 13 out of 129 cases were of death. Therefore, the indications and methods of use should be strictly controlled, and the allergic history of patients should be carefully questioned before medication to strengthen the monitoring of drug use.
